

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical composition comprising

one or more purified flavonoids; and
purified menthol, in a state of purity such that
the purified menthol has a direct antiviral effect in
vitro on rhinovirus in WISH cells, or potentiates the
antiviral effect in vitro of human interferon - α -2b
(Intron A) on rhinovirus in WISH cells, , and
pharmaceutically acceptable excipients.

2. (Cancelled)

3. (Original) The pharmaceutical composition according to claim 1, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt.

4. (Cancelled)

5. (Previously presented) The pharmaceutical composition according to claim 3, wherein said metal is zinc.

6. (Previously presented) The pharmaceutical composition according to claim 3, wherein the metal is zinc selected from the group consisting of Zn²⁺ amino chelates , Zn²⁺ amino

acid chelates, Zn(acetate)₂, Zn²⁺ DL-methionine, Zn²⁺ L-methionine, ZnGluconate and PolaPreZinc ®.

7. (Original) The pharmaceutical composition according to claim 1, wherein said composition is useful for oral and/or nasal administration.

8. (Original) The pharmaceutical composition according to claim 1, wherein said composition is selected from the group consisting of lozenges, troches, capsules, syrups, tablets, lollipops, solutions, dispersions, suspensions, powders, micropheres, chewing tablets, chewing gums, sprays, droppers, pipettes and pills.

9. (Original) The pharmaceutical composition according to claim 1, wherein said composition is a slow-release composition.

10. (Original) The pharmaceutical composition according to claim 1, wherein said composition is lozenges.

11. (Original) The pharmaceutical composition according to claim 1, wherein said composition is essentially free of crude plant extracts.

12. (Original) The pharmaceutical composition according to claim 1, wherein said composition is essentially free of other terpenes than menthol.


13. (Currently Amended) The pharmaceutical composition according to claim 1, wherein said composition is essentially free of one or more compounds selected from

the group consisting of menthone, menthyl acetate, limonene and neomenthol.


14. (Original) The pharmaceutical composition according to claim 1, wherein one or more flavonoids are chelating a metal.

15. (Original) The pharmaceutical composition according to claim 1, wherein the metal is Zn^{2+} .

16. (Original) The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of flavonoids of the general formula:



and the general formula:



Wherein

R2' can be selected from:

-H

-OH

R3' can be selected from:

-H
-OH
-OCH₃
-OCH₂CH₂OH

R4' can be selected from:

-H
-OH
-OCH₃
-OCH₂CH₂OH

R5' can be selected from:

-H
-OH
-OCH₃
-OCH₂CH₂OH

R6' is -H;

R3 including R3₁ and R3₂ can individually be selected from:

-H
-OH
-O-rutinose
-O-glucoside
-O-glucose-p-coumaric acid
-SOH
-O-rhamnose

R4 can be selected from: - (O)
- OH

R5 can be selected from: -H
-OH
-O-CH₂CH₂OH

R6 can be selected from: -H
-OH
-OCH₃

R7 can be selected from: -H
-OH
-O-glucose
-OCH₃
-OCH₂CH₂OH
-O-glucuronic acid
-O-rutinose
-O-rhamnoglucoside

R8 can be selected from: -H
-OH

17. (Original) The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of troxerutin, venoruton, hesperitin, naringenin, nobletin, tangeritin, baicalein, galangin, genistein, quercetin, apigenin, kaempferol, fisetin, rutin, luteolin, chrysins, taxifolin, eriodyctol, catecithin, epicatechin gallate, epigallocatechin gallate, flavone, sideritoflavone, hypolaetin-8-O-Gl, oroxindin, 3-hydroxyflavone, morin, quercetagetin-7-O-Gl, tambuletin,

gossypin, hipifolin, naringin, leucocyanidol,
amentoflavone and derivatives thereof and mixtures thereof

18. (Original) The pharmaceutical composition according to
claim 1, wherein said flavonoid is not a naturally
occurring flavonoid.

19. (Original) The pharmaceutical composition according to
claim 1, wherein said flavonoid is a rutoside.

20. (Original) The pharmaceutical composition according to
claim 1, wherein at least one flavonoid is a rutoside
aglycone.

21. (Original) The pharmaceutical composition according to
claim 1, wherein said flavonoid is a hydroxyethylrutoside.

22. (Original) The pharmaceutical composition according to
claim 1, wherein at least one flavonoid is a
hydroxyethythrutoside aglycone.

23. (Original) The pharmaceutical composition according to
claim 1, wherein said composition comprises a mixture of
hydroxyethylrutosides.

24. (Original) The pharmaceutical composition according to
claim 1, wherein said composition comprises a mixture of
mono-, di-, tri- and tetrahydroxyethylrutosides.

25. (Original) The pharmaceutical composition according to
claim 1, wherein at least one flavonoid is troxerutin.

26. (Original) The pharmaceutical composition according to claim 1, where at least one flavonoid is troxerutin aglycone.

27. (Original) The pharmaceutical composition according to claim 1, wherein the flavonoid is veneruton.

28-57. (Cancelled)

58. (Withdrawn) A method of treatment of a clinical condition or symptoms of a clinical condition in an individual in need thereof, comprising administering to said individual the pharmaceutical composition according to claim 1.

59. (Withdrawn) The method according to claim 58, wherein said clinical condition is a condition relating to common cold.

60. (Withdrawn) The method according to claim 58, wherein the clinical condition is common cold of the upper and/or lower respiratory tract and/or eyes.

61. (Withdrawn) The method according to claim 59, wherein the conditions relating to common cold are viral infections of the upper and/or lower respiratory tract and/or eyes.

62. (Withdrawn) The method according to claim 59, wherein the conditions relating to common cold are bacterial infections of the upper and/or lower respiratory tract and/or eyes.

63. (Withdrawn) The method according to claim 59, wherein the conditions relating to common cold are allergic conditions of the upper and/or lower respiratory tract and/or eyes.

64. (Withdrawn) The method according to claim 59, wherein the conditions relating to common cold are characterized by one or more symptoms of the group comprising coughing, sneezing, muscle pain, sore throat, irritated throat, hoarseness, headache, malaise, chilliness, fever, nasal discharge, nasal obstruction, pain relating to the sinuses, rhinitis, swelling of mucosal membranes, pharyngitis, asthma, and bronchitis.

65. (Withdrawn) The method according to claim 59, wherein the condition relating to common cold is a viral infection caused by or associated with one or more viruses selected from the group consisting of adenoviruses, parvoviruses, picornaviruses, reoviruses, orthomyxoviruses, paramyxoviruses, arenaviruses, caliciviruses, coronaviruses, orthomyxoviruses, rhinovirus, influenza virus, including influenza virus type A and B, echovirus and coxsackie virus.

66. (Withdrawn) The method according to claim 59, wherein the condition relating to common cold is a viral infection caused by or associated with one or more viruses selected from the group consisting of coronaviruses and rhinoviruses.

67. (Withdrawn) The method according to claim 59, wherein the condition relating to common cold is a bacterial

infection caused by or associated with one or more bacteria selected from the group consisting of *Streptococcus pneumoniae*,, *Streptococcus Haemolytiae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*.

68. (Withdrawn) The method according to claim 59, wherein the condition relating to common cold is an allergic condition selected from the group consisting of rhinitis, acute and chronic bronchitis and hay fever.

69. (Withdrawn) The method according to claim 59, wherein the condition related to common cold is an allergic condition characterised by one or more symptoms selected from the group consisting of nasal discharge, nasal congestion, sneezing, cough, swelling of mucosal membranes and rhinitis.

70. (Withdrawn) The method according to claim 58, wherein the administration is to the mucosal membrane of the upper and/or lower respiratory tract and/or of the eyes.

71. (Withdrawn) The method according to claim 58, wherein the administration is topical to the mucosal membrane of the oral cavity.

72-73. (Cancelled)

74. (Withdrawn) A method of reducing the amount of virus in a composition, comprising incubating said composition comprising virus with menthol.

75. (Withdrawn) The method according to claim 74, wherein

said virus is rhinovirus.

76. (Withdrawn) A method of reducing the amount of virus in an individual infection with said virus, comprising administering to said individual a pharmaceutical composition comprising menthol, thereby reducing the amount of said virus in said individual.

77. (Withdrawn) The method according to claim 76, wherein said virus is rhinovirus.

78. (Withdrawn) The method according to claim 76, wherein the method further comprises administering at least one flavonoid to said individual.

79- 80. (Cancelled)

81. (Withdrawn) The method according to claim 58, wherein said flavonoid is a hydroxyethylrutoside.

82. (Withdrawn) The method according to claim 58, wherein at least one flavonoid is troxerutin.

83. (Withdrawn) The method according to claim 58, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt.

84. (Previously Presented) The pharmaceutical composition according to claim 1, wherein said purified menthol is menthol in a substantially purer form than menthol in peppermint oil.

85. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the composition does not comprise peppermint oil.

86. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the composition is essentially free of components of peppermint oil other than menthol.

87. (Previously Presented) The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 90% pure.

88. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the composition is in a form suitable for nasal administration.

89. (Previously Presented) The pharmaceutical composition according to claim 88, wherein the composition is in a form suitable for aerosol administration.

90. (Previously Presented) The pharmaceutical composition according to claim 89, wherein the composition is provided in a pressurized pack which further comprises a propellant.

91. (Currently Amended) The pharmaceutical composition of claim 1, wherein the composition is essentially free of one or more compounds selected from the group consisting of menthone, menthyl acetate, limonene, neomenthol, piperitone, pulegone, β -caryophyllene, β -caryophyllene-epoxide, α -pinene, β -pinene, germacrene D, 1,8-cineol,

linalool, menthofurane, camphene and β -hexenyl phenylacetate.

92 (Previously Presented). The pharmaceutical composition of claim 1, wherein the composition is essentially free of menthone, menthyl acetate, limonene, neomenthol, piperitone, pulegone, β -caryophyllene, β -caryophyllene-epoxide, α -pinene, β -pinene, germacrene D, 1,8-cineol, linalool, menthofurane, camphene and β -hexenyl phenylacetate.

93 (new). The pharmaceutical composition according to claim 87 wherein said composition is essentially free of one or more compounds selected from the group consisting of menthone, menthyl acetate, limonene, neomenthol, piperitone, pulegone, β -caryophyllene, β -caryophyllene-epoxide, α -pinene, β -pinene, germacrene D, 1,8-cineol, linalool, menthofurane, camphene and β -hexenyl phenylacetate.

94 (new). The pharmaceutical composition according to claim 1, wherein said flavonoid by itself does not provide a direct antiviral effect in vitro.

95 (new). The pharmaceutical composition according to claim 87, wherein said flavonoid by itself does not provide a direct antiviral effect in vitro.

96 (new). The pharmaceutical composition according to claim 1, wherein said composition does not increase the growth of rhinoviruses and/or does not down-regulate the

protective action of the natural, human leukocyte interferon system.

97 (new). The pharmaceutical composition according to claim 93, wherein said composition does not increase the growth of rhinoviruses and/or does not down-regulate the protective action of the natural, human leukocyte interferon system.

98 (new). The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 98% pure.

99 (new). The pharmaceutical composition according to claim 1, which has greater antiviral activity than an otherwise identical composition comprising peppermint oil instead of purified menthol.

100 (new). The pharmaceutical composition according to claim 1, wherein the composition has less toxicity than an otherwise identical composition comprising peppermint oil instead of purified menthol.

101 (new). The pharmaceutical composition according to claim 100, wherein the composition has less cytotoxicity in vitro than an otherwise identical composition comprising peppermint oil instead of purified menthol.

102 (new). The composition of claim 1 which has greater antiviral activity than do the purified flavonoids alone.

103 (new). The composition of claim 1 which has a greater

antiviral activity than does the otherwise identical composition in which the purified menthol is replaced by peppermint oil.

104 (new). The composition of claim 1 which has a greater antiviral activity than does the otherwise identical composition in which the composition does not comprise menthol.

105 (new). The composition of claim 1 wherein the antiviral activity is a reduction in cytopathic effect on the WISH cells of at least about 50%.

106 (new). The composition of claim 1 wherein, after 48 hours, the composition achieves on average at least a 75% decrease in symptom score in a treated individual.

107 (new). The composition of claim 1 wherein, after 72 hours, the composition achieves on average at least a 85% decrease in symptom score in a treated individual.

108 (new). The composition of claim 1 wherein, after 48 hours, the composition achieves a greater average decrease in symptom scores than that achieved with an otherwise identical composition which comprises peppermint oil, rather than purified menthol.

109 (new). The composition of claim 1 wherein, after 72 hours, the composition achieves a greater average decrease in symptom scores than that achieved with an otherwise identical composition which comprises peppermint oil, rather than purified menthol.